Effect of Dapagliflozin on Myocardial and Renal Function Following Aortic Valve Stenosis Intervention

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 106 participants.

Also called NCT05241431

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 106 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05241431
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Denmark (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05241431. Randomized; quadruple masking; primary purpose treatment. Start 2022-02-12 (actual); primary completion 2024-03-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Dapagliflozin on Myocardial and Renal Function Following Aortic Valve Stenosis Intervention
Acronym
DAPAS
Condition
Aortic Stenosis
Condition
Left Ventricle Hypertrophied
Intervention (Drug)
SGLT2 inhibitor
Intervention (Drug)
Placebo
Lead sponsor
University of Aarhus (class: other)
Collaborator
Aarhus University Hospital (class: other)

Record details

Record id
cardio:ct-nct05241431
Content hash
21b35158948c27816869797b76c070a6c312ae36aa5267f1d64d5de904b66881